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doi:10.1016/j.jfma.2010.12.003Background/Purpose: Neutropenia is a decrease in the number of circulating neutrophils.
When neutropenia persists for more than 3 months, it becomes chronic. A heterogeneous group
of diseases in children can cause chronic neutropenia. The aim of the present study was to
categorize the diseases and present their clinical manifestations, treatment, and outcomes.
Methods: Medical charts of patients with pediatric chronic neutropenia from the last 21 years
(1988e2008) were reviewed in a tertiary referral center.
Results: Twenty-nine patients were documented during the study period: seven with congen-
ital neutropenia syndromes (CNSs), seven with autoimmune neutropenia (AIN), and 15 with
chronic idiopathic neutropenia (CIN). Three CNS patients had severe chronic neutropenia,
one had the ChediakeHigashi syndrome, one had the hyper-IgM syndrome, one had the
glycogen storage disease type Ib, and one had the Barth syndrome. CNS patients had severe
neutropenia early with frequent infections causing high morbidity and mortality. CNS patients
usually required prophylactic antibiotics, granulocyte colony-stimulating factor therapies, or
umbilical cord blood transplantations to improve or correct clinical conditions. However, most
AIN and CIN patients later recovered spontaneously and did not require granulocyte colony-
stimulating factor therapy. The mean absolute neutrophil count at onset, the mean onset
age of neutropenia, and the mean duration of neutropenia of the two groups of patients did
not significantly differ. Some AIN patients had anemia, and some CIN patients had anemia
and/or thrombocytopenia.
Conclusion: It is difficult and risky to draw any conclusion from such a small-scale study;
however, we believe that promptly diagnosing underlying diseases and administeringof Pediatrics, National Taiwan University Hospital, 8 Chung-Shan South Road, Taipei 10002, Taiwan,
tw (B.-L. Chiang).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
Pediatric chronic neutropenia 221appropriate disease-oriented therapy would be crucial for the treatment of patients with
chronic neutropenia, particularly with regard to CNSs.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Neutropenia is a decrease in the number of circulating
neutrophils and can bemild (1000e1500 106/L), moderate
(500e1000  106/L), or severe (<500  106/L).1e4 The
severity of neutropenia is associated with the susceptibility
to pyogenic infection.2 Additional factors, such as bone
marrow myeloid reserves, speed of onset and duration of
the neutropenia, absolute monocyte count, and the
capacity of phagocytes,5 influence the susceptibility to
infection in neutropenic patients.
Based on duration, neutropenia can be further divided
into acute (or transient) and chronic forms.2 Cytotoxic
effects of drugs or infectious agents often cause the acute
form. Chronic neutropenia has four principal clinical cate-
gories: congenital, cyclic, idiopathic, and autoimmune.6 The
congenital and cyclic categories are regarded as congenital
neutropenia, while the idiopathic and autoimmune cate-
gories are acquired.
The present study reviewed the medical charts of chil-
dren with chronic neutropenia and aimed to clarify the
underlying diseases of our patients with chronic neu-
tropenia and to delineate the clinical manifestations,
treatment, and outcomes of patients with chronic neu-
tropenia based on the four clinical categories.
Materials and methods
Patient source
We reviewed the charts of patients diagnosed with neu-
tropenia during the past 21 years (from January 1988 to
December 2008) in the Department of Pediatrics at the
National Taiwan University Hospital, a tertiary referral
center in Taiwan. Patients who met the criteria of chronic
neutropenia (see below) were enrolled. All patients were
ethnic Chinese. Ethics approval and informed consent were
obtained.
Inclusion and exclusion criteria
Chronic neutropenia was defined as an absolute neutrophil
count (ANC) of 1500 106/L or less for at least 3 months.4,7e9
The duration of neutropenia was defined as the time interval
between the onset and the remission of neutropenia.
Remission was defined as the persistent normalization of the
ANC (>1500  106/L) for more than 3 months. The duration
of follow-ups was defined as the period from the date of
the onset of neutropenia to the date of the last follow-up.
The diagnostic age was defined as the age when the diag-
nosis was made according to clinical manifestations, bone
marrow aspirate (BMA) findings, and laboratory findings with
or without gene mutations analysis. Demographic data,diagnostic evaluation (including complete blood counts,
differentiation counts, BMA findings, genetic studies, and
autoantibodies), treatment, and outcome of patients were
also recorded.
Patients with drug-induced neutropenia, leukemia, mye-
lodysplastic syndrome, aplastic anemia, human immunode-
ficiency virus infection, and systemic autoimmune disease,
such as systemic lupus erythematosus, were excluded.Disease definition
- Congenital neutropenia syndromes (CNSs)da heteroge-
neous groupof inherited disorders,which canbe confirmed
with gene mutation analysis and which include the
following diseases:
Severe congenital neutropenia (SCN, Kostmann
disease): a rare autosomal recessive disorder charac-
terized by persistent agranulocytosis with maturation
arrest at the promyelocyte/myelocyte stage. Known
gene mutations of SCN include ELA2, GFI-1, G-CSFR,
and HAX-1.10e12
ChediakeHigashi syndrome (CHS): a rare autosomal
recessive disorder characterized by recurrent infec-
tion, partial oculocutaneous albinism, and abnormal
large lysosomal granules in nucleated blood cells. A
molecular defect in the lysosomal trafficking regulator
(LYST/CHS1) gene causes CHS.11
Barth syndrome: a rare, X-linkedmitochondrial disorder
characterized by cardiomyopathy, neutropenia, skeletal
myopathy, and growth delay. A gene mutation in the
Taffazin (G4.5/TAZ) gene causes the syndrome.11
Glycogen storage disease (GSD) 1b: a complex meta-
bolic disease characterized by hepatosplenomegaly,
hypoglycemia, lactic acidosis, and neutropenia with
increased susceptibility to pyogenic pathogens. A
genetic defect in the glucose-6-phosphate-transporter
(G6PT) gene causes the disease.11
X-linked Hyper-IgM syndrome (X-linked HIGM), type
1: a disease characterized by normal or elevated serum
IgM levels associated with low or absent IgG, IgA, and
IgE serum levels. A genetic mutation in the CD40 ligand
gene, which is expressed on activated T helper cells,
causes X-linked HIGM.11
- Cyclic neutropeniada congenital benign disease char-
acterized by regular periodic oscillations in the number
of peripheral neutrophils from normal to neutropenia
values, with a mean period of 21  3 days.
- Autoimmune neutropenia (AIN)da disease characterized
by thepresenceof chronic neutropeniaandanti-neutrophil
antibodies.13e15 An indirect granulocyte immunofluores-
cence test (GIFT) can detect anti-neutrophil antibodies.
The present study excluded patients with underlying
systemic autoimmune diseases, infectious diseases,
222 C. Wan et al.neurologic diseases, tumors, and drugs, towhich AINmight
be ascribed.
- Chronic idiopathic neutropenia (CIN)da disease
defined as an ANC of less than 1500  106/L for more than
3 months, the absence of clinical serologic or ultrasonic
evidence of any underlying disease that might be asso-
ciated with neutropenia, the absence of a history of
exposure to irradiation, to which neutropenia might be
ascribed, the absence of a history of use of chemical
compounds and intake of drugs, to which neutropenia
might be ascribed, the presence of a normal bone
marrow karyotype, and negative serum findings in anti-
neutrophil antibodies.9,16e18
Statistics
Statistic analysis was conducted using SPSS 15.0 for
Windows. A p value of less than 0.05 was considered
significant. The mean ANC at onset of AIN patients was
compared with the mean ANC at onset of CIN patients using
Student’s t test. Correlations between gender and disease
recovery in AIN and CIN patients were analyzed using
Fisher’s exact test.
Results
Clinical characteristics and laboratory findings
The present study included 29 patients. Three patients (two
males and one female) had SCN with a mean onset age of
neutropenia at 0.39 years (range: 0.04e0.64 years). The
mean ANC on initial diagnosis was 8.6  106/L (range:
0e25.8  106/L). A male patient diagnosed using BMA
findings lost contact after a follow-up period of 1.89 years
(Table 1). Another female patient confirmed using BMATable 1 Classification and clinical features of patients with co
Type of
congenital
neutropenia
Mutation
gene
Patient
no.
Sex Onset
age (y)
Diagnosis
age (y)
Congenital neutropenia without additional features
SCN ELA2 1 M 0.64 0.98
Not tested 2 M 0.49 0.58
F 0.04 0.05
Congenital neutropenia associated with other syndromes
CHS Not tested 1 F 5.13 5.31
X-linked HIGM CD40L 1 M 3 17.58
GSD, type 1b G6PT 1 M 0.24 0.24
Barth syndrome G4.5/TAZ 1 M 0.05 0.21
CD40L Z CD40 ligand; CHS Z ChediakeHigashi syndrome; ELA2 Z
transporter; GSD Z glycogen storage disease; HIGM: hyper-IGM syndr
neutropenia; UCBT Z umbilical cord blood transplantation.findings received matched unrelated donor (MUD) umbilical
cord blood transplantation (UCBT) [human leukocyte
antigen (HLA) compatibility: 6/6 match] when she was 5
months old due to severe neutropenia with poor response
to granulocyte colony-stimulating factor (G-CSF) therapy
and poor pulmonary condition with frequent, poor-control
infections. (She was found to have lung abscess soon after
birth and received right middle and lower lobes lobectomy
at 2 months old.) The MUD umbilical cord blood was
successfully engrafted, and her neutrophil count increased
to >1000  106/L approximately half a month after
MUDUCBT. Unfortunately, the patient died after MUDUCBT
because of the poor pulmonary condition and complications
(pneumatocele, pneumomediastinum, and pulmonary
hemorrhage) accompanied with severe infections (methi-
cillin-resistent Staphylococcus Aureus (MRSA), Escherichia
coli). The follow-up period was 0.44 years (Table 1). The last
patient diagnosed using BMA findings and gene mutation
analysis (ELA2 gene mutation) received matched related
sibling donor UCBT (HLA compatibility: 6/6 match) due to
severe neutropenia and is currently still alive with regular
follow-ups at our hospital (Table 1). In all these patients,
BMA findings demonstrated typical hypocellular marrow
with maturation arrest at the promyelocyte level (Table 1).
Another four patients (three males and one female) had
congenital neutropenia associated with syndromes, such as
CHS, X-linked HIGM with a CD40 ligand gene mutation,
glycogen storage disease type Ib with a glucose-6-phosphate-
transporter (G6PT) gene mutation, and Barth syndrome with
a G4.5/TAZ gene mutation19 (Table 1). The patient with CHS
diagnosed using clinical manifestations and laboratory find-
ings was in the accelerated phase before receiving partial
matched unrelated donor UCBT (HLA compatibility: 5/6
match) and died shortly after transplantation due to graft
failure and severe infection. The patient with X-linked HIGM
died due to severe sepsis after 12 more years of follow-up.ngenital neutropenia syndromes (CNSs).
ANC at initial
diagnosis
(106/L)
Follow-up
period (y)
Prognosis
0 4.14 Received matched related
sibling donor UCBT
Alive without neutropenia
0 1.89 Loss of follow-up
25.8 0.44 Received MUDUCBT, Died
before 1 y old
585 1.26 Received partial mismatched
unrelated donor UCBT
Died at 6 y old
16,229
(with severe
infection)
12.21 Died at 17 y old due to sepsis
492 4.01 Alive with frequent infections
318 1.85 Alive with frequent infections
elastase 2; G4.5/TAZ Z Taffazin; G6PT Z glucose-6-phosphate-
ome; MUD Z matched unrelated donor; SCN Z severe congenital
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outpatient follow-ups (Table 1).
Three patients were suspected of cyclic neutropenia,
one of whom was lost to follow-up and two of whom did not
show cyclic patterns of neutropenia in the subsequent
follow-ups. Therefore, all three patients were excluded
from the category of cyclic neutropenia.
The present study included seven AIN patients (two
males and five females) and 15 CIN patients (nine males and
six females). Table 2 summarizes demographic, laboratory,
and clinical data of the 22 patients. The mean onset age of
neutropenia was 0.77 years (range: 0.31e1.41 years) for
AIN patients and 0.99 years (range: 0.05e3.87 years) for CIN
patients. The mean ANC at onset of neutropenia in AIN
patients and in CIN patients was 291  253  106/L and
549  478  106/L, respectively. The average duration of
neutropenia was 1.27 years (range: 0.37e2.74 years) for
AIN patients and 2.00 years (range: 0.33e8.60 years) for CIN
patients. The mean onset age of neutropenia, the neu-
tropenia level, and the mean duration of neutropenia did
not significantly differ between the two groups. The
average interval between the date of onset and the date of
diagnosis of neutropenia in AIN and CIN patients was
approximately 2.50 and 3.00 months, respectively. The
average follow-up period for AIN and CIN patients was 2.05
years (range: 0.5e5.53 years) and 2.72 years (range:
0.4e9.78 years), respectively.
The present study also examined other hematological
findings (Table 2) and found that five AIN patients (5/7,Table 2 Basic characteristics of autoimmune neutropenia (AIN)
Patient
no.
Sex Diagnosis Age of
neutropenia at
onset (y old)
ANC at onset
(106/L)
Durati
neutro
(y)
1 M AIN 0.76 0 0.50
2 F AIN 1.05 344 0.37
3 F AIN 0.72 491 1.53
4 F AIN 0.31 201 1.57
5 F AIN 0.47 731 2.74
6 M AIN 1.41 88 1.16
7 F AIN 0.67 179 1.04
8 M CIN 0.95 686 1.07
9 M CIN 0.81 371 0.86
10a F CIN 3.87 62 1.58
11 M CIN 0.94 838 7.43
12 F CIN 0.83 67 3.56
13 M CIN 0.36 215 8.60
14 F CIN 0.73 81 1.00
15 F CIN 0.56 1210 2.28
16 M CIN 0.62 968 0.42
17 M CIN 0.05 672 0.37
18 M CIN 0.38 136 0.42
19a M CIN 1.04 1135 0.33
20a M CIN 0.23 1455 0.53
21b F CIN 1.45 90 1.15
22b F CIN 2.05 244 0.4
ANC Z absolute neutrophil count; F Z female; Hb Z hemoglobin; M
a Patients were diagnosed with thrombocytopenia.
b Patients were detected with positive antiplatelet antibody finding71.4%) had anemia but none had thrombocytopenia during
the follow-up period (Table 2). Nine CIN patients (9/15,
60%) had anemia, and five CIN patients (5/15, 33%) had
transient thrombocytopenia or antiplatelet antibodies in
their serum during the follow-up period (Table 2). Three
CIN patients (3/15, 20%) had both anemia and transient
thrombocytopenia or antiplatelet antibodies (patients 10,
20, and 22 in Table 2). Only one of the three patients
recovered from neutropenia, and no other systemic
diseases or autoimmune diseases were found in the three
patients during the follow-up period.
Bone marrow studies were performed in two AIN
patients (2/7, 28.6%) and in five CIN patients (5/15, 33.3%).
BMA results demonstrated normo- or hypercellularity with
normal or low numbers of mature neutrophils in AIN
patients and a normal cellularity or a shift to the left of the
granulocyte series in CIN patients.Infections
Infections were common in patients with chronic neu-
tropenia. All SCN patients developed severe infections,
including sepsis or septic shock, systemic fungal infection,
pneumonia, lung abscess, pneumatocele, and urinary tract
infection. The ANCs were extremely low, and patients
responded poorly to G-CSF therapy. Common infection sites
were the skin, umbilicus, and respiratory and urinary
tracts. The pathogens included Candida albicans, E coli,and chronic idiopathic neutropenia (CIN) patients.
on of
penia
Follow-up
period (y)
Lowest Hb
level (g/dL)
Anemia during
follow-up period
Current
status
0.50 10.2 Y Alive
2.36 10.6 N Alive
1.53 10.3 Y Alive
2.23 8.8 Y Alive
5.53 10.3 Y Alive
1.16 12.5 N Alive
1.04 9.6 Y Alive
1.07 10.3 Y Alive
0.86 11.4 N Alive
2.30 8.4 Y Alive
7.43 11.9 N Alive
6.85 10. Y Alive
9.78 9.3 Y Alive
1.00 9.4 Y Alive
2.28 11.6 N Alive
0.68 11.3 N Alive
3.73 8.8 Y Alive
0.42 10.2 Y Alive
0.65 11.2 N Alive
0.53 8.4 Y Alive
2.83 9.3 Y Alive
0.4 10.6 N Alive
Z male; N Z no; Y Z yes.
s.
224 C. Wan et al.coagulase (e) Staphylococcus spp., and Klebsiella
pneumoniae.
In addition to frequent bacterial infections, the patient
with CHS entered into an “accelerated phase” and had an
EBV-induced hemophagocytic syndrome (lymphoma-like
syndrome) before UCBT. The patient with X-linked HIGM
also had frequent respiratory tract bacterial infections
requiring hospitalization treatment (six times within 1 year)
and died during the follow-up period due to severe sepsis.
The patient with GSD type 1b developed severe neu-
tropenia soon after birth and was frequently admitted to
the hospital due to neutropenic fever and infection in the
first 3 years (15 times within 3 years), but was responsive to
G-CSF therapy (5 mg/kg/day). The Barth syndrome patient
developed cardiomyopathy, neutropenia, and metabolic
acidosis when the patient was approximately 1 month old.
Frequent neutropenia and respiratory, gastrointestinal, and
urinary tract infections caused the patient to be hospital-
ized eight times during the follow-up period (1.85 years).
The neutropenic condition of the patient improved only
transiently with G-CSF therapy (10 mg/kg/day).
Five of the seven AIN patients (71.4%) and 10 of the 15
CIN patients (66.7%) had infections that required hospital-
ization. The most common infection sites of AIN patients
were the upper and lower respiratory tract, cutaneous
tissue, tonsils, ears, and gastrointestinal tract. In CIN
patients, the upper and lower respiratory tract, cutaneous
tissue, gastrointestinal tract, ears, and urinary tract were
most susceptible to infection (Fig. 1). Identified pathogens
of AIN and CIN patients included viruses (Human herpes
virus-6, Enterovirus, Herpes simplex virus) and bacteria
(Salmonella spp., E coli, Group A Streptococcus, Strepto-
coccus pneumoniae, Staphylococcus aureus, and Pseudo-
monas spp.), but did not include fungal pathogens.
However, AIN and CIN patients rarely had recurrent
severe infections that required frequent hospitalization. In
the present study, all AIN and CIN patients had less than
three hospitalizations within a year during the follow-up
period, and more than half of the patients had less than twoFigure 1 Types of infections in patients with autoimmune
neutropenia (AIN), chronic idiopathic neutropenia (CIN), and
severe congenital neutropenia (SCN). AGE Z acute gastroen-
teritis; LRTIZ lower respiratory tract infection; URTIZ upper
respiratory tract infection; UTI: urinary tract infection.hospitalizations within a year during the follow-up period.
No patients with either AIN or CIN suffered from long-term
consequences after infections.
Treatment and outcome
Oral or intravenous antibiotics were administered to
patients with bacterial infections. CNS patients (except one
individual who was treated with UCBT and recovered with
normal neutrophil) received prophylactic antibiotics treat-
ment, but AIN and CIN patients did not. G-CSF was applied
in 5/7 (71.4%), 1/7 (14.3%), and 4/15 (26.7%) of CNSs, AIN,
and CIN patients, respectively (Table 3). A dosage of 5 mg/
kg/day was administered at the beginning of G-CSF treat-
ment when patients had severe neutropenia (ANC
<500  106/L) with underlying infections and was increased
to 10 mg/kg/day if the ANC was still below 1000  106/L
during G-CSF application. The neutrophil count increased
briefly after G-CSF administration in CNSs patients.
All CNSs patients required intensive treatment, and one
SCN and one CHS patient died after receiving UCBTs (Tables
1and 3). Other enrolled CNSs patients did not receive
UCBTs. The patient with X-linked HIGM died due to sepsis at
the age of 17 years (Table 1). Even though other patients
with GSD type 1b and Barth syndrome are still alive at
present and receive regular checkups at our hospital, they
suffered from frequent infections and usually required
hospitalization for intensive medical care. All living CNS
patients did not recover from neutropenia except the one
who received UCBT.
Three AIN patients (3/7, 42.9%, all recovered sponta-
neously) recovered from neutropenia (Table 3) with a mean
recovery time of 14 months. Eight CIN patients (8/15,
53.3%) also recovered (three received G-CSF treatment and
five recovered spontaneously) (Table 3) with a mean
recovery time of 24.6 months. All AIN patients who recov-
ered were female (3/3, 100%), while only three of the CIN
patients who recovered were female (3/8, 37.5%). Gender
and neutropenia recovery did not correlate in both AIN and
CIN patients (p > 0.05).
Discussion
Only one of the SCN patients was confirmed using gene
mutation analysis (ELA2 gene). The estimated incidence of
SCN is approximately 1e5/1,000,000.9,20e22 In one study,
the percentage of ELA2 gene mutation in SCN patients was
as high as 50%, but GFI-1 and G-CSFR gene mutations were
quite rare.10 The frequency of HAX-1 gene mutation was
unknown.10 A model has been proposed to explain the role
of ELA2 gene mutation in cyclic neutropenia and SCN.10 In
the pathogenesis of cyclic neutropenia and SCN, the ELA2
gene mutation leads to a production of misfolded neutro-
phil elastase proteins in the endoplasmic reticulum and to
an activation of the unfolded protein response, resulting in
apoptosis of granulocytic precursors.10,12,23
No CNS patients recovered spontaneously in the present
study. All patients with SCN, Barth syndrome, and GSD type
1b received G-CSF treatment for neutropenia. The biolog-
ical effects of G-CSF include stimulated neutrophil
progenitor proliferation and differentiation, decreased
Table 3 Treatments and outcomes of patients with autoimmune neutropenia (AIN), chronic idiopathic neutropenia (CIN), and
congenital neutropenic syndromes (CNSs).
No. of patients with
G-CSF usage (%)
No. of patients who
received UCBT (%)
No. of patients
who died (%)
No. of patients who recovered
from neutropenia (%)
AIN (n Z 7) 1/7 (14.3%) 0/7 (0) 0/7 (0) 3/7 (42.9%)
CIN (n Z 15) 4/15 (26.7%) 0/15 (0) 0/15 (0) 8/15 (53.3%)
SCN (n Z 3) 3/3 (100%) 2/3 (66.7%) 1/3(33.3%) 2/3 (66.7%)
CHS (n Z 1) 0/1 (0) 1/1 (100%) 1/1 (100%) 0/1 (0)
X-linked HIGM (n Z 1) 0/1 (0) 0/1 (0) 1/1 (100%) 0/1 (0)
GSD, type 1b (n Z 1) 1/1 (100%) 0/1 (0) 0/1 (0) 0/1 (0)
Barth syndrome (n Z 1) 1/1 (100%) 0/1 (0) 0/1 (0) 0/1 (0)
AIN Z autoimmune neutropenia; CHS Z ChediakeHigashi syndrome; CIN Z chronic idiopathic neutropenia; G-CSF Z granulocyte
colony-stimulating factor; GSD Z glycogen storage disease; HIGM Z hyper-IGM syndrome; SCN Z severe congenital neutropenia;
UCBT Z umbilical cord blood transplantation.
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antigen expression, enhanced phagocyte function, and
increased levels of soluble FcrRIIIb, which sequesters
autoantibodies.5,24 The only way to cure diseases such as
SCN, CHS, and X-linked HIGM, is through bone marrow
transplantation or UCBT.
In the present study, three patients (two SCN and one
CHS) received UCBT for correction of the underlying
diseases, and only one SCN patient is still alive. The survival
rate of patients after UCBT was only 33% (1/3). A review
article revealed that the 1- and 2-year overall survival rate
for children who received unrelated UCBT because of
hematological malignancies and marrow failure syndromes
was 29e58% and 35e53%, respectively.25 Bizzetto et al26
demonstrated that the survival rate of SCN patients
receiving related and unrelated UCBT was 100% (n Z 1)
and 73.3% (n Z 15), respectively. Carlsson et al27 reported
seven patients with SCN who received hematopoietic stem
cell transplantation (HSCT), and the overall survival rate
was 71%. In the present study, although the overall survival
rate after UCBT was low, the death of the two patients was
associated with some underlying conditions.
In the dead SCN patient, the MUD umbilical cord blood
was successfully engrafted and neutrophil count increased
(>1000  106/L) approximately half a month after UCBT.
However, the patient died later due to the poor pulmonary
condition, pulmonary complications, and severe infections.
The result indicates that the general condition of the patient
also influenced the survival rate of patients receiving UCBT.
It seems that transplantation related mortality (graft
failure), disease status, and severe infections cause the
death of the CHS patient in this study. The graft failure might
be due to inappropriate umbilical cord blood, which came
from a partial matched unrelated donor. HLA match have
been reported as a factor impacting on the survival of chil-
dren receiving unrelated UCBT.28 Furthermore, the CHS
patient was already in the accelerated phase before UCBT,
which might lead to an increased mortality rate of trans-
plantations. Eapen et al29 reported that mortality was
highest in patients who have entered the accelerated phase
of the disease before transplantation. Only four out of 11
patients with an active disease at transplantation survived
(survival rate was about 36%).29
Cardiac transplantation can cure cardiomyopathy of
patients with Barth syndrome,19 and liver transplantationcan cure the enzymatic defect of patients with glycogen
storage disease type 1b.
In the present study, BMA findings of AIN patients
showed the occurrence of normo- or hypercellularity with
normal or low numbers of mature neutrophils. These find-
ings are consistent with previous reports.5,22 BMA findings
of CIN patients revealed a normal cellularity or a shift to
the left in the granulocyte series and are similar to BMA
findings of adult CIN patients.9,18,30
AIN is diagnosed by the presence of anti-neutrophil
autoantibodies.13e15 Until now, no single method can
identify all anti-neutrophil autoantibodies. In our hospital,
we adopted indirect GIFT to identify anti-neutrophil anti-
bodies. This method does not require the collection of
neutrophils from neutropenic patients and does not require
experienced observers.5 However, the method also has
several defects, such as a high frequency of false negative
findings and false positive findings.5
The possible pathological roles of anti-neutrophil auto-
antibodies include phagocytosis of sensitized neutrophils,
opsonic activity, complement-fixing abilities, and interfer-
ence with neutrophil functions.5,31 However, the exact
mechanisms of CIN are still unknown.
The male/female ratio of the AIN patients of the present
study was 2:5, which is different from the ratios in previous
studies.22,32,33 The ratio might differ due to the different
geographic areas and the smaller patient size used in the
present study, which could cause a sample bias. Previous
studies have reported that AIN is most frequently found in
newborn infants, is diagnosed in the first few months of
life, and patients often spontaneously recover at the age of
2e3 years.22,32,34 Our data are similar to these findings.
Five of the AIN patients (5/7, 71.4%) had anemia during the
follow-up period. It is likely that AIN might contribute to
anemia in these AIN patients.
In the present study, male CIN patients outnumbered
female patients (M/F Z 9:6). The patients usually had
neutropenia at a young age (approximately 1 year old), and
most recovered spontaneously (8/15, 53.3%), which is
similar to the results of a previous study.33 However, our
results differ from a study in CIN adults, in which the male/
female ratio was 1:5.35 In the present study, more male
children with CIN recovered spontaneously, possibly
explaining sex ratio differences between children and
adults with CIN.
226 C. Wan et al.Compared to adults with CIN,18,36 children with CIN has
no significant splenomegaly upon diagnosis but have
a higher percentage of anemia (9/15, 60%). In adults with
CIN, the frequency of anemia is estimated to be approxi-
mately 14.2%, and the possible underlying pathogenetic
mechanism is disease chronicity.9,36 Young children might
have anemia due to disease chronicity and susceptibility to
viral infections, which result in anemia of inflammation.
Other etiologies such as physiological anemia might also
contribute to the occurrence of anemia. Thrombocytopenia
was found in 20% (3/15) of the children with CIN in our
study, and has been found in approximately 10% of adults
with CIN in previous studies.18,37
Infection is the most dangerous complication of neu-
tropenia. In the present study, SCN and CHS patients were
more likely to have severe systemic viral, bacterial, or
fungal infections besides local viral and bacterial infec-
tions. Other CNS patients also suffered from frequent viral
and bacterial infections, which caused mortality and
morbidity (Table 1). However, except for one CIN patient
with systemic bacteremia, AIN and CIN patients only
suffered from local infections.
AIN and CIN in children are generally benign diseases. In
the present study, a large portion of AIN and CIN patients
recovered spontaneously. When AIN and CIN patients
suffered from severe neutropenia, the optimal method to
correct it was G-CSF usage. In the present study, two AIN
and three CIN patients received G-CSF treatment, and all
responded with elevated neutrophil count.
Limitations of this study include the small number of
enrolled patients, the lack of gene mutation analysis in
some CNS patients, and a possible incorrect categorization
of patients into AIN or CIN groups due to the relative low
sensitivity and specificity of indirect GIFT.
Although it is difficult and risky to draw any conclusion
based on such a small-scale study, we believe that children
with CNSs require early correct diagnosis and a more
aggressive treatment to cure both the underlying diseases
and severe infections. In addition, these children also
require intensive medical care to improve morbidity and
mortality. In contrast, children with AIN and CIN are subject
to better clinical courses, and most of them only have to be
treated conservatively.
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